2DR Stock Chart & Stats
€51.50
€1.80(4.27%)
At close: 4:00 PM EDT
€51.50
€1.80(4.27%)
Day’s Range― - ―
52-Week Range€33.60 - €121.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.76B
Enterprise Value€999.46M
Total Cash (Recent Filing)€320.68M
Total Debt (Recent Filing)€29.09M
Price to Earnings (P/E)14.6
Beta0.63
Next Earnings
Nov 02, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.66
Shares Outstanding28,910,376
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€61.70Price Target Upside19.81% Upside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)1.1
Revenue Forecast (FY)€760.22M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetA debt-free balance sheet with $415 million of cash and investments gives Inspire substantial flexibility to absorb reimbursement disruption, fund patient-access initiatives, and sustain operations without relying on external financing. This supports resilience and long-term strategic investment.
High Margins And Improving ProfitabilityVery high gross margins and a return to solid net profitability indicate attractive underlying economics for the therapy system. Even with slower recent revenue growth, this earnings base can support continued investment, operating resilience, and cash generation over the next several quarters.
Clinical Evidence Supports DifferentiationPublished evidence showing favorable clinical outcomes versus CPAP can strengthen physician confidence and patient consideration of Inspire therapy. Over time, credible outcomes may support adoption, referrals, and reimbursement discussions, reinforcing the product’s position in obstructive sleep apnea care.
Bears Say
Reimbursement DisruptionThe estimated $120 million to $130 million annual impact shows that coding and reimbursement changes are materially affecting demand conversion and revenue recognition. Continued uncertainty around WISeR and payment rules could constrain center activity, complicate planning, and pressure results through the next several quarters.
Revenue And Margin PressureRecent revenue contraction and expected further decline indicate that near-term growth momentum has weakened despite the company’s attractive product economics. Lower sales create unfavorable operating leverage, increase execution pressure, and may limit profitability until reimbursement and channel conditions stabilize.
Restructuring And Earnings VolatilityThe planned restructuring introduces meaningful near-term charges, including noncash impairments and employee separation costs, while the company reorganizes operations. Combined with guidance for elevated effective tax rates, these items can make reported earnings volatile and obscure the pace of underlying recovery.
Inspire Medical Systems News
2DR FAQ
What was Inspire Medical Systems’s price range in the past 12 months?
Inspire Medical Systems lowest stock price was €33.60 and its highest was €121.90 in the past 12 months.
What is Inspire Medical Systems’s market cap?
Inspire Medical Systems’s market cap is €1.76B.
When is Inspire Medical Systems’s upcoming earnings report date?
Inspire Medical Systems’s upcoming earnings report date is Nov 02, 2026 which is tomorrow.
How were Inspire Medical Systems’s earnings last quarter?
Inspire Medical Systems released its earnings results on Aug 03, 2026. The company reported €0.125 earnings per share for the quarter, beating the consensus estimate of -€0.211 by €0.336.
Is Inspire Medical Systems overvalued?
According to Wall Street analysts Inspire Medical Systems’s price is currently Undervalued.
Does Inspire Medical Systems pay dividends?
Inspire Medical Systems does not currently pay dividends.
What is Inspire Medical Systems’s EPS estimate?
Inspire Medical Systems’s EPS estimate is 0.08.
How many shares outstanding does Inspire Medical Systems have?
Inspire Medical Systems has 28,910,376 shares outstanding.
What happened to Inspire Medical Systems’s price movement after its last earnings report?
Inspire Medical Systems reported an EPS of €0.125 in its last earnings report, beating expectations of -€0.211. Following the earnings report the stock price went up 20.495%.
Which hedge fund is a major shareholder of Inspire Medical Systems?
Currently, no hedge funds are holding shares in DE:2DR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspire Medical Systems Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€61.70 (19.81% Upside)
€61.70 (19.81% Upside)
Blogger Sentiment
Bullish
DE:2DR Sentiment 82%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth €51.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.80%
12-Months-Change
Fundamentals
Return on Equity
17.62%
Trailing 12-Months
Asset Growth
15.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inspire Medical Systems
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
2DR Company Deck
2DR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: meaningful near-term headwinds from coding and reimbursement disruption depressed top-line growth (Q2 revenue down 7.6% and a full-year disruption impact estimated at $120M–$130M), drove elevated tax and restructuring items, and widened near-term guidance. Offsetting these challenges, management delivered profitability and positive operating cash flow ahead of expectations, possesses a strong cash position ($415M, no debt), announced Project Horizon to create $30M of reinvestment capacity, and highlighted strong clinical evidence and favorable proposed CMS facility reimbursement changes (+12% hospital, +15% ASC for 2027). Given the comparable weight of material negatives (revenue/headwinds, restructuring, reimbursement uncertainty) and material positives (cashflow, balance sheet, clinical momentum and planned reinvestment), the overall tone is balanced with a path to recovery but meaningful near-term uncertainty.View all DE:2DR earnings summaries2DR Revenue Breakdown
97.02% U.S.
2.98% Other
2DR Stock 12 Month Forecast
Average Price Target
€61.70
▲(19.81% Upside)